Skip to content

Study · Non-randomized trial · n = 20 · 2002

5 results

Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or in combination with GHRH: comparison with the insulin tolerance test.

Petersenn S, Jung R, Beil FU

European journal of endocrinology1 May 2002Cited by 17 (Europe PMC)

PMID11980622 (opens in a new tab)DOI10.1530/eje.0.1460667 (opens in a new tab)PepBankPUB-11980622
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults tested for pituitary or adrenal disease, GHRP‑6 alone gave a mean GH peak of 1.3 microg/l in GH-deficient patients versus 25.7 microg/l in GH-sufficient patients.

    In plain wordsGHRP‑6 alone raised growth hormone much less in patients with GH deficiency than in patients with normal GH.

    Peptide
    GHRP-6
    Outcome
    Not applicableGH peak after GHRP-6 alone, GH deficient versus GH sufficient
    Study

    n = 20

    Comparator
    GH sufficient patients
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kgAs given in this study (human).

    Measurements

    GH mean peak
    1.3 microg/l
    GHD group
    GH mean peak
    25.7 microg/l
    GS group

    Source sentences

    Summary
    For the GHRP-6 test, the GH mean peak was 1.3 microg/l (+/-0.6, 0.1-6.7) in the GHD group versus 25.7 microg/l (+/-5.5, 7.7-54.2) in the GS group.
    1 context sentence
    Summary · context
    Twenty patients underwent an ITT for suspected pituitary or adrenal disease.
  2. 02HumanNon-randomized trialSafety outcome

    In adults tested for pituitary or adrenal disease, the only side effects seen during GHRP‑6 administration were flush symptoms.

    In plain wordsIn adults tested for pituitary or adrenal disease, the only side effects seen with GHRP‑6 were flushing symptoms.

    Peptide
    GHRP-6
    Outcome
    Not applicableSide effects during GHRP-6
    Study

    n = 20

    Outcome group
    Adverse events · Whole body
    Studied dose
    1 microg/kgAs given in this study (human).

    Source sentences

    Summary
    During administration of GHRP-6, the only side effects observed were flush symptoms.
    1 context sentence
    Summary · context
    Twenty patients underwent an ITT for suspected pituitary or adrenal disease.
  3. 03HumanNon-randomized trialEfficacy outcome

    In adults tested for GH deficiency, a peak GH below 7 microg/l after GHRP‑6 alone identified all patients with GH deficiency as defined by the insulin tolerance test.

    In plain wordsIn adults tested for GH deficiency, a GHRP‑6 growth hormone peak below 7 microg/l identified all patients with GH deficiency.

    Peptide
    GHRP-6
    Outcome
    Not applicableDiagnostic GH cut-off for GHRP-6 test
    Study

    n = 20

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kgAs given in this study (human).

    Measurements

    GH peak cut-off
    < 7 microg/l
    GHRP-6 test

    Source sentences

    Summary
    Peak GH levels below 7 microg/l for the GHRP-6 test and below 13 microg/l for the combined GHRP-6+GHRH test identified all patients with GH deficiency correctly as defined by ITT.
    1 context sentence
    Summary · context
    Twenty patients underwent an ITT for suspected pituitary or adrenal disease.

Studies that did not test the peptide alone2

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 04HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    In adults tested for pituitary or adrenal disease, GHRP‑6 plus GHRH gave a mean GH peak of 4.0 microg/l in GH-deficient patients versus 54.7 microg/l in GH-sufficient patients.

    In plain wordsThe GHRP‑6 plus GHRH test raised growth hormone much less in patients with GH deficiency than in patients with normal GH.

    Peptide
    GHRP-6
    Outcome
    Not applicableGH peak after GHRP-6 plus GHRH, GH deficient versus GH sufficient
    Study

    n = 20

    Comparator
    GH sufficient patients
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH mean peak
    4 microg/l
    GHD group
    GH mean peak
    54.7 microg/l
    GS group

    Source sentences

    Summary
    After GHRP-6+GHRH, the GH mean peaks were 4.0 microg/l (+/-1.3, 0.2-11.9) versus 54.7 microg/l (+/-11.1, 13.9-136.0) respectively.
    1 context sentence
    Summary · context
    Twenty patients underwent an ITT for suspected pituitary or adrenal disease.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 05HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    In adults tested for GH deficiency, a peak GH below 13 microg/l after GHRP‑6 plus GHRH identified all patients with GH deficiency as defined by the insulin tolerance test.

    In plain wordsIn adults tested for GH deficiency, a growth hormone peak below 13 microg/l after GHRP‑6 plus GHRH identified all patients with GH deficiency.

    Peptide
    GHRP-6
    Outcome
    Not applicableDiagnostic GH cut-off for GHRP-6 plus GHRH test
    Study

    n = 20

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH peak cut-off
    < 13 microg/l
    GHRP-6 plus GHRH test

    Source sentences

    Summary
    Peak GH levels below 7 microg/l for the GHRP-6 test and below 13 microg/l for the combined GHRP-6+GHRH test identified all patients with GH deficiency correctly as defined by ITT.
    1 context sentence
    Summary · context
    Twenty patients underwent an ITT for suspected pituitary or adrenal disease.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.